Clinical Trials Logo

Clinical Trial Summary

To evaluate the bioavailability of a single oral dose of the Acetylsalicylic Acid containing dry powder 500 mg in comparison to the bioavailability of a single oral dose of aspirin tablets and aspirin effervescent tablets in healthy adults.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02394093
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date February 2015
Completion date March 2015

See also
  Status Clinical Trial Phase
Completed NCT00941057 - Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium Phase 1
Completed NCT01707407 - A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects Phase 1
Terminated NCT04320771 - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1
Completed NCT00855660 - Effect of Riociguat on Bone Metabolism Phase 1
Completed NCT03929861 - Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations Phase 1
Completed NCT01489488 - Relative Bioavailability and Food Effect Study Phase 1
Completed NCT01044524 - Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion Phase 1
Terminated NCT04322253 - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight Phase 1